Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06326645 | Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome | EARLY_PHASE1 | RECRUITING | 6 | — | — | Mar 3, 2025 | Feb 1, 2026 | Feb 12, 2026 | 1 | United States |
Change in ostomy output from baseline over the entire 12-week treatment period as average weekly ostomy output at week 12.
| Arm | Type | Description |
|---|---|---|
| Crofelemer Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Crofelemer Oral Product | DRUG | Crofelemer powder for solution (50g and 100g) or Crofelemer Powder for Oral Solution (100 mg/mL or 30 mg/mL vials for reconstitution and oral dosing) |
Inclusion Criteria: 1. Patients must understand and provide written informed consent before they can participate in the study. They must understand the study procedures of the trial and be willing to complete the required assessments; 2. Male and female patients aged ≥ 18 years; 3. SBS patients wit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Teduglutide |
| Jaguar Health, Inc. | JAGX | 1 | PHASE2 | Crofelemer for |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | — | Undisclosed |